A genetic map built from roughly 900 rats points to a hepatic cocaine metabolizing gene as the most surprising hit, reframing addiction as a whole body problem and handing the field its first concrete peripheral drug target.
For decades, addiction research has treated cocaine use disorder as a brain-circuit story: dopamine, glutamate, reward, relapse. A new genome-wide association study published in Nature Communications argues the organ doing the talking may be the liver, not the brain. Working in roughly 900 genetically diverse Heterogeneous Stock rats, a University of California San Diego team led by Montana Kay Lara, Olivier George, and Abraham A. Palmer found that the strongest new signal tied to compulsive-like cocaine taking sits inside a cluster of carboxylesterase genes called Ces1, the rat orthologue of human CES1, an enzyme that lives in the liver and does most of the body's work of breaking cocaine down.
That is a meaningful reframing. It suggests that how fast a body clears cocaine, not just how a brain responds to it, may set the threshold between controlled use and compulsive use. "It was an aha moment when we saw this hit," George, a co-corresponding author and behavioral addiction researcher at UC San Diego, told Genetic Engineering & Biotechnology News. The surprise was the tissue, not the statistic.
The method is what makes the claim worth taking seriously. Heterogeneous Stock rats are an outbred line that captures genetic variation closer to a human population than a typical inbred lab strain. The team ran an extended-access cocaine self-administration protocol designed to model the three behaviors that matter clinically: escalation of intake over time, motivation under a progressive-ratio schedule, and compulsive-like responding even when paired with an aversive cue. Across that battery, six major loci reached genome-wide significance. Five were previously known addiction-related genes, including Trak2, FAM53B, NCOR2, LPHN2, and FAM78B, the kind of replication that builds confidence that the assay is reading something real. The Ces1 cluster was the new one.
Replication mattered here. Trak2 had already shown up in human cocaine use disorder GWAS, and seeing it light up in rats was a deliberate cross-species test: if the same locus appears in two independent species, two different genetic backgrounds, and two different behavioral assays, the signal is unlikely to be noise. The Ces1 finding is younger and weaker. It is an association in a rat model, not a confirmed human addiction gene. CES1 has appeared in some human substance-use analyses, but it has not been validated in cocaine use disorder cohorts at the level of a drug target. That gap, between a rat signal and a clinical lever, is the single most important caveat in this paper.
Why it matters beyond the biology: cocaine use disorder is one of the few major psychiatric indications with no FDA-approved pharmacotherapy. Roughly five million Americans reported past-year cocaine use in the 2022 National Survey on Drug Use and Health cited in the paper's introduction, and about 1.4 million met criteria for cocaine use disorder. Twin studies put the heritability of cocaine dependence near 70 percent, but SNP-based heritability is only 27 to 30 percent, and the human GWAS that exist are underpowered, which is exactly why a peripheral, druggable, and biologically interpretable target like CES1 is worth chasing.
The team is now doing the work that determines whether this is a target or a curiosity. They are using the Preclinical Addiction Biobanks at UC San Diego, which archive blood, urine, brain, and tissue from addiction-modeled rodents, to functionally validate Ces1 variants, and they plan to use CRISPR and pharmacological tools to test whether slowing cocaine metabolism blunts compulsive-like intake. If those experiments hold, CES1 joins a small list of metabolic enzymes that psychiatry has spent serious money on before, including MAO-B and COMT, but this time for a stimulant addiction rather than depression or Parkinson's.
The honest read for clinicians, families, and people with cocaine use disorder is cautious. A liver enzyme associated with compulsive cocaine taking in rats is, at best, a candidate. It is not a cure, not a breakthrough, and not a treatment that exists. What it is, is the first concrete peripheral target the field has for an indication that has gone four decades without a single approved drug, and a clean mechanistic reason to think that drug development for stimulant use disorder may have been looking in the wrong organ. The next eighteen months of functional validation work, not this paper, are the part worth watching.